share_log
Benzinga ·  Mar 11 20:29
Lyell Immunopharma Expects Cash And Equivalents Of $383.5M As Of December 31, 2024, To Support Advancing Pipeline Into 2027
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 280

Recommended

Write a comment